-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
A2ti-2
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/482646-13-9.gif)
| Category | Human papillomavirus (HPV) |
| CAS | 482646-13-9 |
| Description | A2ti-2 is a selective and low-affinity inhibitor of annexin A2/S100A10 heterotetramer (A2t) with an IC50 of 230 μM. A2ti-2 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. It protects against human papillomavirus type 16 (HPV16) infection. |
Product Information
| Synonyms | 2-{5-[(2-methylphenoxy)methyl]-4-phenyl-1,2,4-triazol-3-ylthio}acetamide; Acetamide, 2-[[5-[(2-methylphenoxy)methyl]-4-phenyl-4H-1,2,4-triazol-3-yl]thio]-; 2-({5-[(2-Methylphenoxy)methyl]-4-phenyl-4H-1,2,4-triazol-3-yl}sulfanyl)acetamide |
| IUPAC Name | 2-[[5-[(2-methylphenoxy)methyl]-4-phenyl-1,2,4-triazol-3-yl]sulfanyl]acetamide |
| Molecular Weight | 354.43 |
| Molecular Formula | C18H18N4O2S |
| Canonical SMILES | CC1=CC=CC=C1OCC2=NN=C(N2C3=CC=CC=C3)SCC(=O)N |
| InChI | InChI=1S/C18H18N4O2S/c1-13-7-5-6-10-15(13)24-11-17-20-21-18(25-12-16(19)23)22(17)14-8-3-2-4-9-14/h2-10H,11-12H2,1H3,(H2,19,23) |
| InChIKey | DRZJLOOZLBTLAL-UHFFFAOYSA-N |
| Boiling Point | 626.5±65.0°C at 760 mmHg |
| Purity | ≥98% |
| Density | 1.3±0.1 g/cm3 |
| Solubility | Soluble in DMSO |
| Appearance | White to Off-white Solid |
| Storage | Store at 2-8°C |
| Complexity | 433 |
| Exact Mass | 354.11504700 |
| In Vitro | A2ti-2 is an annexin A2-S100A10 protein-protein interaction blocker, and is less effective with <50% reduction in HPV16 PsV infection achieved at 100 μM. A2ti-1 decreases HPV16 entry with a 20% reduction at 100 μM. |
| Target | Virus Protease; HPV |
| XLogP3-AA | 2.7 |
